Subject matter of the present invention is a method for monitoring a therapy in a subject, wherein the subject is under treatment with an anti-Adrenomedullin (ADM) binder selected from the group comprising an antibody, antibody-fragment and/or non-Ig scaffold, comprising determining the level of a fragment of pre-pro-Adrenomedullin selected from the group comprising Midregional Proadrenomedullin (MR-proADM), C-terminal Proadrenomedullin (CT-proADM) and/or Proadrenomedullin N-terminal 20 peptide (PAMP) or fragments thereof in a bodily fluid obtained from said subject; and correlating the level of said fragment of pre-pro-Adrenomedullin with the subject's clinical/medical status of health and/or the risk for an adverse outcome and/or the requirement for adapting therapeutic measures.

The inventors have produced two high specificity and high affinity monoclonal antibodies that bind to human neuromedin U (NMU). Methods and compositions are provided for treating an individual in need thereof (e.g., an individual who is obese and/or has diabetes) by administering an anti-NMU/NMUR agent (e.g., an anti-NMU antibody). For example, methods and compositions are provided for increasing circulating insulin in an individual. Methods and compositions are also provided for detecting neuromedin U (NMU) (e.g., in a biological sample such as serum). Methods and compositions are also provided for predicting whether an individual will develop diabetes and/or PDAC, and for identifying an individual who would benefit from administration of an anti-NMU/NMUR agent.

The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.

The present invention is directed to a method for treating or preventing cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an adropin stimulating agent. Further provided are a method and a kit for diagnosing or prognosing liver metastases in a subject.

The present invention relates to the screening, diagnosis, prognostic evaluation, and treatment or prevention of age associated inflammation, chronic inflammation, and inflammatory diseases. In particular, the present invention relates to treating or preventing inflammatory diseases (e.g. rheumatoid arthritis or spondyloarthritis) or patients with inflammatory peripheral GnRH with GnRH antagonists or drugs that lower the effects of GnRH.

The invention relates to a method for the diagnosis, prognosis, prediction, risk assessment and/or risk stratification of a subsequent trauma-related complication in a polytrauma patient, comprising providing a sample of said patient, wherein the sample is isolated from the patient after the polytrauma, determining a level of pro ADM or fragment(s) thereof in said sample, wherein said level of pro ADM or fragment(s) thereof correlates with the likelihood of a subsequent trauma-related complication

Disclosed herein are devices, systems, methods and kits for performing immunoassay tests to detect for at least progesterone or analytes of progesterone on a sample in association with diagnosing problems and issues associated with corpus luteum functionality. The immunoassay devices and methods may be used in conjunction with diagnostic reader systems and/or a base unit for obtaining a sensitive readout of the immunoassay results. The methods disclosed herein may also incorporate steps associated with evaluating the urine of a sample for the presence of an estrogen metabolite and/or luteinizing hormone.

The present invention provides systems, devices, and methods for point-of-care and/or distributed testing services. The methods and devices of the invention are directed toward automatic detection of analytes in a bodily fluid. The components of the device can be modified to allow for more flexible and robust use with the disclosed methods for a variety of medical, laboratory, and other applications. The systems, devices, and methods of the present invention can allow for effective use of samples by improved sample preparation and analysis.

The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.

The invention pertains to a method for the prognosis and/or risk assessment and/or diagnosis of a major adverse cardio- or cerebrovascular event (MACCE) in a patient who underwent gastrointestinal surgery, the method comprising the steps of: i) providing a sample of a bodily fluid from said patient, ii) determining in said sample the level of a biomarker selected from the group consisting of copeptin, troponin and brain natriuretic peptide (BNP), iii) determining at least one additional parameter of said patient, iv) combining the biomarker level determined in step ii) and the additional parameter determined in step iii) into a combined assessment, and v) correlating the combined assessment to said at least one of prognosis, risk assessment and diagnosis of a MACCE in said patient. The invention further pertains to a kit for carrying out the method, a computer and a computer program product comprising computer-executable code being configured to carry out steps iv) and/or v) of the method of the invention.